Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Event, Product/Service, Trade Show

SINOVAC to Showcase Products at CPHI Frankfurt

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the world's largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio. The Company will showcase the only inactivated COVID-19 vaccine approved for children as young as 6-months old, CoronaVac®; the quadrivalent influenza vaccine, QIV; the world-leading enterovirus type 71 vaccine, Inlive®; the varicella vaccine which provides 100% protection against moderate and severe cases; and two WHO prequalified vaccines: the hepatitis A vaccine, Healive® and the Sabin-strain inactivated polio vaccine.

Helen Yang, Chief Business Officer of SINOVAC said, "SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHI's in-person event for the first time since the outbreak of the COVID-19 pandemic globally. As always, we highly value the platform's business potential, and plan to showcase many of our best products, especially those approved by the WHO and distributed to many countries around the world. We are eager to introduce our recent cutting-edge technologies to our global partners and to develop more business opportunities."

To meet SINOVAC on site, you are welcome to visit Booth#41G20, or contact Alice Chen via [email protected] to schedule appointments.


Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, poliomyelitis, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company's website at www.sinovac.com.

These press releases may also interest you

at 14:20
Published Author: World-renowned trauma psychologist Sherry Walling, Ph.D., examines the inner workings of grief through her lens. The author of Touching Two Worlds lost two family members in very different ways. Her personal insight offers a map for...

at 14:10
For a fourth year, Black Rock Coffee Bar, a national boutique coffee chain, is partnering with JoyRx, the mission delivery of Children's Cancer Association, to help bring joy to kids and teens around the United States who are facing pediatric cancer...

at 14:10
The "Methylsulfonylmethane Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to  ResearchAndMarkets.com's offering. The purpose of...

at 14:00
The nature of the work of public safety personnel (PSP) means they are continuously exposed to potentially psychologically traumatic events. This can impact their mental health and well-being and increase their risk for developing post-traumatic...

at 14:00
The "Global Facial Aesthetics Market Size, Share & Industry Trends Analysis Report By Product (Dermal fillers, Botulinum toxin, Microdermabrasion, Chemical peels), By Application, By End User, By Regional Outlook and Forecast, 2022 - 2028" report has...

at 14:00
Codoxo, a trusted provider of healthcare artificial intelligence solutions for healthcare payers, agencies and pharmacy benefits managers (PBMs), today announced the release of its Forensic AI Alerts eBook: 2022 FWA Trends to Inform 2023 Cost...

News published on 28 october 2022 at 05:05 and distributed by: